These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 6487365

  • 1. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C, Vidgen D.
    Biochem Pharmacol; 1984 Oct 15; 33(20):3177-81. PubMed ID: 6487365
    [Abstract] [Full Text] [Related]

  • 2. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC, Markman M, Cleary S, Howell SB.
    Cancer Res; 1986 Jun 15; 46(6):3168-72. PubMed ID: 3698032
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC, Howell SB.
    Cancer Res; 1985 Aug 15; 45(8):3598-604. PubMed ID: 4016741
    [Abstract] [Full Text] [Related]

  • 4. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW, Mutter G, Hankerson JG, Reck LJ, Harley C, Han N, Ardalan B, Cysyk RL, Johnson RK, Jayaram HN, Cooney DA.
    Cancer Res; 1981 Mar 15; 41(3):894-904. PubMed ID: 7459875
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
    Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Casper ES, Young CW.
    Cancer Res; 1983 May 15; 43(5):2317-21. PubMed ID: 6187448
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
    Markman M, Chan TC, Cleary S, Howell SB.
    Cancer Chemother Pharmacol; 1987 May 15; 19(1):80-3. PubMed ID: 3815730
    [Abstract] [Full Text] [Related]

  • 7. Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells.
    Chan TC, Howell SB.
    Eur J Cancer Clin Oncol; 1989 Apr 15; 25(4):721-7. PubMed ID: 2714348
    [Abstract] [Full Text] [Related]

  • 8. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES, Vale K, Williams LJ, Martin DS, Young CW.
    Cancer Res; 1983 May 15; 43(5):2324-9. PubMed ID: 6831457
    [Abstract] [Full Text] [Related]

  • 9. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
    Yang JL, Fernandes DJ, Wheeler KT, Capizzi RL.
    Int J Radiat Oncol Biol Phys; 1996 Mar 15; 34(5):1073-9. PubMed ID: 8600090
    [Abstract] [Full Text] [Related]

  • 10. Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues.
    Zaharevitz DW, Grubb MF, Hyman R, Chisena C, Cysyk RL.
    J Natl Cancer Inst; 1993 Apr 21; 85(8):662-6. PubMed ID: 8468725
    [Abstract] [Full Text] [Related]

  • 11. Modulation of the activity of PALA by dipyridamole.
    Chan TC, Young B, King ME, Taetle R, Howell SB.
    Cancer Treat Rep; 1985 Apr 21; 69(4):425-30. PubMed ID: 3857969
    [Abstract] [Full Text] [Related]

  • 12. Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine 5'-monophosphate.
    Lynch TP, Paran JH, Paterson AR.
    Cancer Res; 1981 Feb 21; 41(2):560-5. PubMed ID: 7448803
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK, Inouye T, Goldin A, Stark GR.
    Cancer Res; 1976 Aug 21; 36(8):2720-5. PubMed ID: 1064466
    [Abstract] [Full Text] [Related]

  • 14. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA.
    J Natl Cancer Inst; 1982 Feb 21; 68(2):227-31. PubMed ID: 6950156
    [Abstract] [Full Text] [Related]

  • 15. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B, Jayaram HN, Johnson RK.
    Cancer Res; 1983 Apr 21; 43(4):1598-601. PubMed ID: 6831405
    [Abstract] [Full Text] [Related]

  • 16. In vitro cytotoxic effect of N-(phosphonacetyl)-L-aspartic acid in liposome against C-26 murine colon carcinoma.
    Kim JS, Heath TD.
    Arch Pharm Res; 2000 Apr 21; 23(2):167-71. PubMed ID: 10836745
    [Abstract] [Full Text] [Related]

  • 17. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 18. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET, O'Connell MJ, Kovach JS.
    Cancer; 1983 Aug 15; 52(4):615-8. PubMed ID: 6861099
    [Abstract] [Full Text] [Related]

  • 19. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C.
    Recent Results Cancer Res; 1980 Aug 15; 74():65-71. PubMed ID: 7444150
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA, Durrani FA, Rustum YM.
    Cancer Res; 1993 Apr 01; 53(7):1560-4. PubMed ID: 8453623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.